Journals / Erciyes Tıp Dergisi / 2007 / Cilt: 29 - Sayı: 2

Treatment in classic Kaposi's sarcoma

Klasik Kaposi sarkomunda tedavi

Pages
128–131
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Five-year disease-free and overall survival rates were 44% and 82%, respectively.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To evaluate the patients with classic Kaposi’s sarcoma which is frequently encountered in Mediteranean and East European countries.
📊
Key Findings & Data:Patients and Methods: Patients diagnosed and treated between 2000 and 2005 were included in this study.
💡
Conclusion & Impact:Five-year disease-free and overall survival rates were 44% and 82%, respectively.
🔬Design:Research Article
📍Scope:2000 Verileri
⚙️Variables:Domain Parameters

Abstract

Purpose: To evaluate the patients with classic Kaposi’s sarcoma which is frequently encountered in Mediteranean and East European countries. Patients and Methods: Patients diagnosed and treated between 2000 and 2005 were included in this study. Patients were evaluated according to their age, sex, tumor localization, number, size and stage as well as local (surgery, radiotherapy) and systemic (chemotherapy) treatment methods. In addition, during follow-up, time to local recurrence, distant metastases, and death were recorded and survival analysis was performed.Results: There were 12 patients with classic Kaposi’s sarcoma of which eight were male. Tumors were located in the extremities in all patients. There were only skin lesions in all patients and eight patients had stage I whereas two patients had stage II classic Kaposi’s sarcoma. All tumoral lesions were surgically removed in ten patients. During the follow-up period, four patients had local recurrence and two patients presented with pulmonary metastases. Five-year disease-free and overall survival rates were 44% and 82%, respectively. Conclusion: It is possible to obtain a long-term survival using surgery, radiotherapy and chemotherapy in combination

Özet

Amaç: Klasik Kaposi sarkomu tanısı alan hastaları uygulanan tedaviler ve sonuçları açısından incelemek. Hastalar ve Yöntem: 2000-2005 yılları arasında teşhis ve tedavi edilen hastalar çalışmaya alındı. Hastalar, yaş, cinsiyet, tümörün yerleşim yeri, sayısı, boyutu ve evresi ile uygulanan lokal (cerrahi ve radyoterapi) ve sistemik tedaviler (kemoterapi) açısından değerlendirildi. Ayrıca, hastalar takip edilerek lokal nüks ve uzak organ metastazı görülme süreleri ile sağkalım süreleri kaydedilerek sağkalım analizleri yapıldı. Bulgular: Klasik Kaposi sarkomu olan sekizi erkek 12 hasta mevcuttu ve tümör hastaların tümünde ekstremitelerde yerleşmişti. Hastaların tümünde sadece lokal cilt lezyonları saptandı ve on hastada evre I ve iki hastada da evre II klasik Kaposi sarkomu mevcuttu. On hastaya cerrahi eksizyon uygulanarak tüm lezyonları çıkartıldı. Hastaların takiplerinde dördünde lokal nüks ve ikisinde de akciğerde uzak metastaz saptandı. Hastaların beş yıllık hastalıksız ve tüm sağkalım oranları, sırasıyla, %44 ve %82 idi. Sonuç: Klasik Kaposi sarkomunda cerrahi, radyoterapi ve kemoterapiyi birlikte kullanarak uzun süreli sağkalım elde etmek olasıdır.

🔖

Cite This Article

ATALAY, C., ALTINOK, M., KARAMAN, N., YILMAZ, K. B. (2022). Treatment in classic Kaposi's sarcoma. Erciyes Tıp Dergisi, Cilt: 29 - Sayı: 2, 128–131. https://ajindex.com/articles/502742

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Schwartz RA. Kaposi�s sarcoma: an update. J Surg Oncol 2004; 87: 146-151
  2. Coþkun Hş, Er Ö, Özbalcı D, Özkan M, Altınbaş M. Klasik Kaposi sarkomu. Sözel bildiri, XVI. Ulusal Kanser Kongresi Bildiri Özet Kitabı, sayfa 133
  3. Brambilla L, Boneschi V, Taglioni M, Ferrucci S. Staging of classic Kaposi�s sarcoma: a useful tool for therapeutic choices.Eur J Dermatol 2003; 13: 83-86
  4. Brenner B, Weismann-Brenner A, Rakowsky E, et al. Classical Kaposi sarcoma: prognostic factor analysis of 248 patients.Cancer 2002; 95: 1982-1987
  5. Pantanowitz L, Dezube BJ. Advances in the pathobiology and treatment of Kaposi sarcoma. Curr Opin Oncol 2004; 16:443-449
  6. Cattelan AM, Trevenzoli M, Aversa SML. Recent advances in the treatment of AIDS-related Kaposi�s sarcoma. Am J Clin Dermatol 2002, 3, 451-462
  7. Bower M, Palmieri C, Dhillon T. AIDS-related malignancies:changing epidemiology and the impact of highly active antiretroviral therapy. Curr Opin Infect Dis 2006; 19: 14-19
  8. Gao S-J, Kingsley L, Hoover DR, et al. Seroconversion to antibodies against Kaposi's sarcoma associated herpes virus related latent nuclear antigens before the development of Kaposi's sarcoma. N Engl J Med 1996; 335: 233-241
  9. Becker G, Bottke D. Radiotherapy in the management of Kaposi's sarcoma. Onkologie 2006; 29: 329-333
  10. Fenig E, Brenner B, Rakowsky E, Lapidoth M, Katz A,Sulkes A. Classic Kaposi sarcoma: experience at Rabin Medical Center in Israel. Am J Clin Oncol 1998; 21: 498-500
  11. Yildiz F, Genc M, Akyurek S, et al. Radiotherapy in the management of Kaposi's sarcoma: comparison of 8 Gy versus 6 Gy. J Natl Med Assoc 2006; 98: 1136-1139
  12. Kirova YM, Belembaogo E, Frikha H, et al. Radiotherapy in the management of epidemic Kaposi�s sarcoma: a retropective study of 643 cases. Radiother Oncol 1998;46:19-22
  13. Fardet L, Stoebner PE, Bachelez H, et al. Treatment with taxanes of refractory or life-threatening Kaposi sarcoma not associated with human immunodeficiency virus infection. Cancer 2006; 106: 1785-1789
  14. Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi�s sarcoma:results of a randomized phase III clinical trial. J Clin Oncol 1998; 16: 2445-2451
  15. Osoba D, Northfelt DW, Budd DW, Himmelberger D. Effect of treatment on health-related quality of life in acquired immunodeficiency syndrome (AIDS)-related Kaposi�s sarcoma:a randomized trial of pegylated-li